NORCROSS, Ga., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the Nonalcoholic Steatohepatitis (NASH) Workshop hosted by JMP Securities on Thursday, February 27, 2014 in New York, NY. NASH, a progressive liver disease caused by the accumulation of fat in the liver leading to inflammation and fibrosis, is estimated to affect nine to 15 million people, including children, in the United States.
Help employers find you! Check out all the jobs and post your resume.
